Vitamin D levels in Mediterranean breast cancer patients compared with those in healthy women. (October 2018)

• Record Type: Journal Article
• Authors: Pineda-Moncusí, Marta; Garcia-Perez, Miguel Angel; Rial, Abora; Casamayor, Guillem; Cos, Maria Lourdes; Servitja, Sonia; Tusquets, Ignasi; Diez-Perez, Adolfo; Cano, Antonio; Garcia-Giralt, Natalia; Nogues, Xavier
• Is Part Of: Maturitas. Volume 116(2018)
• Page Start: 83
• Page End: 88
• Publication Date: 2018-10
• Subjects: VDR vitamin D receptor -- 25(OH)D vitamin D -- B-ABLE Barcelona–Aromatase induced Bone Loss in Early breast cancer -- BC breast cancer patients -- BMI body mass index -- PCA principal component analysis -- ChT chemotherapy -- ChT+ patients with chemotherapy -- ChT− patients without chemotherapy; Vitamin D -- Breast cancer -- Chemotherapy -- B-ABLE cohort study; Climacteric -- Periodicals; Menopause -- Periodicals; Climacteric -- Periodicals; Geriatrics -- Periodicals; Menopause -- Periodicals; Middle Aged -- Periodicals; Climatère -- Périodiques; Ménopause -- Périodiques; Climacterium; Climacteric; Menopause; Electronic journals; Periodicals; 612.66
• DOI: 10.1016/j.maturitas.2018.07.015
• Languages: English
• ISSNs: 0378-5122

Abstract

Highlights: Vitamin D insufficiency is common in healthy postmenopausal women. Breast cancer patients showed lower vitamin D levels than the healthy population. Vitamin D levels dramatically decreased after recent chemotherapy. Vitamin D levels had partially recovered by 2 years after chemotherapy. Vitamin D supplementation might be considered for breast cancer patients, especially after chemotherapy. Abstract: Objectives: To evaluate the vitamin D status of postmenopausal women with early estrogen-receptor-positive breast cancer and to compare it with that of healthy postmenopausal women from the same Mediterranean region. Study design and outcome measures: Data from 691 breast cancer (BC) patients in the B-ABLE cohort were analyzed after recent cancer intervention (recent-BC) or after a minimum of two years since this intervention (long-term-BC). Patients were also stratified by previous chemotherapy exposure (ChT+ and ChT−). Plasma levels of 25-hydroxyvitamin D [25(OH)D] (25(OH)D) were compared with data from 294 healthy women (non-BC) by linear regression to estimate β-coefficients using non-BC participants as the reference group. Age, body mass index and season of blood extraction were selected as potential confounders. Results: Of the recent-BC patients, 23.7% had 25(OH)D deficiency, compared with 17.7% of the long-term-BC group, and just 1.4% of the non-BC participants. Most of the women were located in the insufficient 25(OH)D category regardless of study group. BC patients had significantly lower 25(OH)D levels than non-BC participants (adjusted β-coefficients: −4.84 [95%CI -6.56 to -3.12] in recent-BC, and −2.05 [95%CI −4.96 to −0.14] in long-term-BC). Among BC patients, the lowest 25(OH)D levels were found in the recent-BC (ChT+) group (p < 0.001). No differences were found between the long-term-BC (ChT−), long-term-BC (ChT+) and recent-BC (ChT−) groups. Among the BC ChT+ patients, the recent-BC group had significantly lower 25(OH)D levels than the long-term-BC group (p < 0.001). Conclusion: Severely reduced 25(OH)D levels were detected in patients with breast cancer, particularly after recent chemotherapy. These 25(OH)D levels had partially recovered over the long term, but still remained much lower than in the healthy population.